

Tangram Therapeutics plc
("Tangram" or "the Company")

Tangram Therapeutics - Convertible Loan Note Instrument

London, UK, 15 September 2026 – Tangram Therapeutics ("Tangram"), a company committed to unlocking transformative RNAi medicines for meaningful patient impact, today announces that it has entered into a convertible loan note instrument with M&G Investment Management Limited and Ora Capital Limited. The loan notes are convertible into ordinary shares of the Company in certain circumstances and, a noteholder's right to convert the loan notes prior to 11.59pm on 2 February 2027 (being the end of the transition period under the City Code on Takeovers and Mergers, when the City Code ceases to apply to the Company), may require the approval of independent shareholders of a Rule 9 waiver in accordance with the City Code. Further details will be provided to shareholders by mail in due course and at such time, this announcement will be removed from the Tangram website.

About Tangram Therapeutics

Tangram Therapeutics is a clinical-stage biotech committed to unlocking transformative RNAi medicines for meaningful patient impact. Real progress in the treatment of diseases with high unmet need calls for drug discovery that goes beyond the obvious. Tangram purposefully pursues differentiated targets, developing innovative medicines enabled by GalOmic, the Company's proprietary RNAi chemistry platform designed to selectively silence disease-driving genes in hepatocytes. This is the foundation of Tangram's Relentless Medicine Discovery. Faster, smarter development of medicines designed for real-world patient impact.

Learn more at www.tangramtx.com.

Media Contact

press@tangramtx.com

Investor Relations Contact

IR@tangramtx.com